For the Inventor, By the Inventor

Enter assignee name

The Green Cross Corporation

USPTO Granted Patents = 264

% Expired Patents = 3.8

CIPO Patents = 2

EPO Patents = 23

Trademarks = 2

Forward Citations = 2,991

Loading Chart...

Loading Chart...

559 inventors (with patents filed for the assignee):

Kazumasa Yokoyama (72 out of 80 patents)

Tadakazu Suyama (47 out of 47 patents)

Chikara Fukaya (33 out of 34 patents)

4. Satoshi Funakoshi (25 out of 25 patents)

5. Taizo Ono (24 out of 24 patents)

6. Takao Ohmura (21 out of 24 patents)

7. Yahiro Uemura (20 out of 25 patents)

8. Yoshio Arakawa (20 out of 20 patents)

9. Yoshihisa Inoue (18 out of 18 patents)

10. Yoshio Tsuda (18 out of 18 patents)

11. Hee Jeong Seo (14 out of 25 patents)

12. Youichiro Naito (14 out of 15 patents)

13. Suk Ho Lee (13 out of 31 patents)

14. Min Ju Kim (13 out of 20 patents)

15. Masahiro Watanabe (13 out of 16 patents)

Core Competencies:

Bispecific Antibody

Cancer Treatment

SGLT2 Inhibitors

Anti-CD3 Antibody

Pharmaceutical Composition

Epidermal Growth Factor Receptor

Recombinant Human Serum Albumin

Immunoglobulin Purification

Therapeutic Agent

Infusion Preparation

Antimicrobial Agent

Protein Purification

264 patents: Sort by Forward Citations

1. 12747427 - METHOD FOR PRODUCTION OF VARICELLA ZOSTER VIRUS SURFACE PROTEIN ANTIGEN (2026-09-29),

2. 12673944 - Compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same (2026-07-07),

3. 12534518 - FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF (2026-01-27),

4. 12522602 - Derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same (2026-01-13),

5. 12338237 - Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same (2025-06-24),

6. 12319746 - Bispecific antibody specifically binding to GPNMB and CD3, and use thereof (2025-06-03),

7. 12247082 - Highly efficient anti-TFPI antibody composition (2025-03-11),

8. 11584777 - Method for purifying a sulfatase protein (2023-02-21),

9. 11535646 - Method for purification of immunoglobulin (2022-12-27),

10. 11524054 - Method of treating anemia using long-acting EPO formulation (2022-12-13),

11. 11498965 - Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same (2022-11-15),

12. 11447559 - Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same (2022-09-20),

13. 11401343 - Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same (2022-08-02),

14. 11332528 - Anti-CEACAM1 antibody and use thereof (2022-05-17),

15. 11198733 - Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor (2021-12-14),

Company Overview

The Green Cross Corporation, headquartered in Osaka, Japan, specializes in the development and manufacturing of innovative antibody therapeutics. The company focuses on advanced treatments for cancer, leveraging technologies such as bispecific antibodies and SGLT2 inhibitors. Their expertise extends to pharmaceutical compositions involving anti-CD3 antibodies and epidermal growth factor receptors, as well as the purification of immunoglobulins. Green Cross is committed to enhancing patient outcomes through cutting-edge biopharmaceutical solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

264 Patents

#66 in Osaka

#581 in Japan

#3,321 in the World

The Green Cross Corporation

Forward Citations = 2,991

559 inventors:

Kazumasa Yokoyama (72 out of 80 patents)

Tadakazu Suyama (47 out of 47 patents)

Chikara Fukaya (33 out of 34 patents)

4. Satoshi Funakoshi (25 out of 25 patents)

5. Taizo Ono (24 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: The Green Cross Corporation. Retrieved from https://idiyas.com/company/green-cross

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…